Revive develops a new tannin-chitosan composite as a psychedelics delivery system.
Exploring the companies and themes that make up this emerging and exciting new sector
PharmaDrug Inc. Enters into Definitive Agreement to Acquire First Smart Shop in the Netherlands
PharmaDrug takes its first step to begin retail psychedelic sales in the legal market for psychedelic drugs in the Netherlands.
Canadians LEGALLY Using Psilocybin: A Big Step Forward
For the first time since the 1970's, a small group of Canadians have been granted (federal) permission to legally use psilocybin for medicinal purposes.
Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness
Mydecine's Vancouver-based affiliate, Mindleap Health™ is adding three digital therapy programs.
Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.
Novamind acquires Utah-based Cedar Psychiatry and Cedar Clinical Research for CAD$3.05 million.
Big Pharma: Friend or Foe of Psychedelic Drugs?
Big Pharma has strong incentives to embrace psychedelics. But will its predatory business model turn drug companies against these drugs?
Palliative Canadians endure punishing waits while Health Minister delays approval of Psilocybin mushrooms; TheraPsil expands effort to Ontario
More pressure on Ottawa to move forward on legalization of psilocybin.
Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness
Numinus establishes a partnership with one of Canada's largest addiction treatment organizations.
MindMed Completes Dosing 18-MC Phase 1 Study
MindMed completes its Phase 1 study of its non-hallucinogenic formulation of ibogaine.
Mydecine Building Its Psychedelics Footprint
Mydecine Innovations Group has been building momentum with a string of recent announcements.
Psychedelics Investing 101: Creating a Basket of Psychedelics Stocks
Intelligent diversification is the key to investing in this emerging industry.
Are Psychedelics The Answer For Addiction?
Globally, over 1 billion people are substance abusers. The U.S. addiction treatment market is already a $35 billion per year industry. Psychedelic drugs may be the (better) answer.